(2265–2289) Rheumatoid Arthritis – Treatment Poster III

Tuesday, October 28, 2025

10:30 AM - 12:30 PM Central Time

Location: Hall F1

CE: 0.00

Presentations:

10:30 AM - 12:30 PM Central Time

ACKR1 and Leukopenia in Patients with Rheumatoid Arthritis Treated with Disease Modifying Antirheumatic Drugs
Abstract Poster Presenter: Daniela Chavez de Paz Solis, BS (she/her/hers) – National Institutes of Health
10:30 AM - 12:30 PM Central Time

Agreement Between Two Rheumatoid Arthritis Response Measures Across Bts DMARD Treatment Classes in a Large, Prospective Observational Study Supporting the Development and Clinical Validation of a Novel Blood based Precision Medicine Test
Abstract Poster Presenter: Jason Carlson, MPH – Aqtual Inc
10:30 AM - 12:30 PM Central Time

Arrhythmia Risk in Diabetic Rheumatoid Arthritis Patients: Comparative Analysis of IL-6 Inhibitors versus TNF-α Inhibitors
Abstract Poster Presenter: Sila Mateo Faxas, MD (she/her/hers) – Good Samaritan Hospital
10:30 AM - 12:30 PM Central Time

Assessing the Real-world Impact of Earlier Initiation of Adalimumab vs. Conventional Synthetic Dmards on Healthcare Resource Utilization in Patients with Rheumatoid Arthritis in Europe
Abstract Poster Presenter: Dr. Carmen Bremer, PhD – Sandoz International GmbH
10:30 AM - 12:30 PM Central Time

Association of Semaglutide Prescription with Improved Joint Outcomes in Rheumatoid Arthritis Patients
Abstract Poster Presenter: Yazin Hindosh, BS (he/him/his) – University of Arizona College of Medicine Tucson
10:30 AM - 12:30 PM Central Time

Cardiovascular Outcomes in Diabetic Rheumatoid Arthritis Patients: TNF-α Inhibitors versus IL-6 Inhibitors
Abstract Poster Presenter: Sila Mateo Faxas, MD (she/her/hers) – Good Samaritan Hospital
10:30 AM - 12:30 PM Central Time

Changes of B Cell Subsets During Treatment with Abatacept in Patients with Rheumatoid Arthritis
Abstract Poster Presenter: Lazaros Sakkas, MD, PhD, DM, FRCP – IASO General Hospital
10:30 AM - 12:30 PM Central Time

Combination Therapy with TNF Inhibitors and JAK Inhibitors in Multi-Drug-Resistant Rheumatoid Arthritis: A Case Series from the RA UCLouvain Brussels Cohort
Abstract Poster Presenter: Francesco Natalucci, MD, PhD – UCLouvain University
10:30 AM - 12:30 PM Central Time

Differential Impact of Certolizumab Pegol, Etanercept, and Adalimumab on Rheumatoid Factor Reduction and Seroconversion in Rheumatoid Arthritis: A Propensity Score–Matched Study
Abstract Poster Presenter: Clementina Lopez-Medina, MD, PhD (she/her/hers) – Reina Sofia University Hospital
10:30 AM - 12:30 PM Central Time

Effect of Online Continuing Education on Advancing Care for Rheumatoid Arthritis: A Real-World Outcome Analysis
Abstract Poster Presenter: Nimish Mehta, PhD,MBA – Medscape
10:30 AM - 12:30 PM Central Time

Effectiveness of Upadacitinib in Patients with Rheumatoid Arthritis in Canadian Real-World Practice: Final Results from the CLOSE-UP Post-Marketing Observational Study
Abstract Poster Presenter: Louis Bessette, MD, MSc – Centre de l'Ostéoporose et de Rhumatologie de Québec
10:30 AM - 12:30 PM Central Time

Effects of Transcutaneous Auricular Vagus Nerve Stimulation on Disease Activity in Patients with Rheumatoid Arthritis: A Pilot Study
Abstract Poster Presenter: Yuichiro Fujieda, MD,PhD – Hokkaido University Hospital
10:30 AM - 12:30 PM Central Time

Efficacy of Ivarmacitinib in Patients with Moderate-to-severe Rheumatoid Arthritis Stratified by Baseline Characteristics: A Post-hoc Study of a Phase III Clinical Trial
Abstract Poster Presenter: Yuan Xue, MD – Zhongshan Hospital Xiamen University
10:30 AM - 12:30 PM Central Time

Immunophenotyping of peripheral blood mononuclear cells reveals potential cellular biomarkers of disease in rheumatoid arthritis
Abstract Poster Presenter: John Bui, BSc – Sonoma Biotherapeutics
10:30 AM - 12:30 PM Central Time

Impact of Baseline Cardiovascular Risk Factors Comorbidities on an Adalimumab Biosimilar Efficacy, Quality of Life and Safety In Patients with Patients with Moderately to Severely Active Rheumatoid Arthritis: Results from the AURIEL-RA study
Abstract Poster Presenter: Christopher Edwards, MD;FRCP – University Hospital Southampton
10:30 AM - 12:30 PM Central Time

Impact of Rheumatoid Arthritis Therapeutic Classes on Risk of All-Cause Mortality and All-Cause Cancer: A Population-Based Cohort Study
Abstract Poster Presenter: Bindee Kuriya, MD, MS – University of Toronto - Toronto
10:30 AM - 12:30 PM Central Time

Impact of Upadacitinib on Glucocorticoid Reduction in Patients with Moderate-to-Severe RA Who Achieved and Maintained Clinical Remission in the 2-Year UPHOLD Study
Abstract Poster Presenter: FRANK BUTTGEREIT, MD – Charité University Medicine Berlin
10:30 AM - 12:30 PM Central Time

Importance Of Fc Region On Therapeutic Survival In Rheumatoid Arthritis Patients With Anti-TNF Therapy
Abstract Poster Presenter: Iago Alcántara Álvarez, MD – Hospital Universitari i Politènic La Fe
10:30 AM - 12:30 PM Central Time

Interpretable Ensemble Machine Learning Explaining Nonadherence and the Risk of Nonpersistence of Targeted Disease-Modifying Antirheumatic Agents in Older Adults with Rheumatoid Arthritis
Abstract Poster Presenter: Yinan Huang, PhD, MS – Department of Pharmacy Administration, University of Mississippi
10:30 AM - 12:30 PM Central Time

Key factors in optimizing the dose of Baricitinib in rheumatoid arthritis: a study based on routine clinical practice and its therapeutic implications
Abstract Poster Presenter: Daniel Campos-Martin, n/a (he/him/his) – Rheumatology Department, Donostia University Hospital
10:30 AM - 12:30 PM Central Time

Long-Term Cardiovascular Risk Following Tnfi vs Triple Therapy: A Post-hoc Analysis Integrating Randomized Clinical Trial and Electronic Health Record Data
Abstract Poster Presenter: Jennifer Hanberg, MD – Brigham and Women's Hospital
10:30 AM - 12:30 PM Central Time

Long-Term Prevention of RA in high-risk individuals after a 6-Month Placebo-Controlled Intervention with Abatacept -The ARIAA Trial
Abstract Poster Presenter: Koray Tascilar, MD – Friedrich Alexander University of Erlangen Nuremberg, Universitätsklinikum Erlangen Department of Medicine-3 Rheumatology and Immunology
10:30 AM - 12:30 PM Central Time

Neuroimmune modulation for the Treatment of Rheumatoid Arthritis: Results at 12 months from a Randomized, Sham-Controlled, Double-Blind Study
Abstract Poster Presenter: John Tesser, MD, FACP, MACR – Arizona Arthritis & Rheumatology Associates
10:30 AM - 12:30 PM Central Time

Progressive Interstitial Lung Disease associated to Rheumatoid Arthritis despite Abatacept therapy. Data from a large national multicenter cohort of 526 patients
Abstract Poster Presenter: Ana Serrano-Combarro, MD – Division of Rheumatology, Hospital Universitario Marques de Valdecilla, IDIVAL, Inmunopathology group, Santander
10:30 AM - 12:30 PM Central Time

Synovium-on-a-chip – Development of a Humanized Rheumatoid Arthritis Model that Mimics Disease and Patient Biological Heterogeneity
Abstract Poster Presenter: Theresa Wampler Muskardin, MD – Hospital for Special Surgery, Weill Cornell Medicine